Emyria Enters Agreement with Medibank for Treatment-Resistant Depression Program, Shares Jump 6%

MT Newswires Live

Sep 22, 2025

Emyria (ASX:EMD) entered a multi-year agreement with Medibank (ASX: MPL) to fund treatment for screened and eligible customers admitted into the firm's treatment-resistant depression program at Perth Clinic, according to a Monday Australian bourse filing.

The firm said that this was the first time a major private health insurer was funding a psychotherapy-led treatment-resistant depression program in Australia.

The firm's shares jumped 6% in recent trading on Monday and earlier reached their highest point in over a year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569272444"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569272444\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569272444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569272444","market":"sh","top_or_hot":-1,"title":"Emyria Enters Agreement with Medibank for Treatment-Resistant Depression Program, Shares Jump 6%","media":"MT Newswires Live","content":"<html><body><p> Emyria (ASX:EMD) entered a multi-year agreement with Medibank (ASX: MPL) to fund treatment for screened and eligible customers admitted into the firm's treatment-resistant depression program at Perth Clinic, according to a Monday Australian bourse filing.</p><p>The firm said that this was the first time a major private health insurer was funding a psychotherapy-led treatment-resistant depression program in Australia.</p><p>The firm's shares jumped 6% in recent trading on Monday and earlier reached their highest point in over a year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emyria Enters Agreement with Medibank for Treatment-Resistant Depression Program, Shares Jump 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmyria Enters Agreement with Medibank for Treatment-Resistant Depression Program, Shares Jump 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-22 10:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Emyria (ASX:EMD) entered a multi-year agreement with Medibank (ASX: MPL) to fund treatment for screened and eligible customers admitted into the firm's treatment-resistant depression program at Perth Clinic, according to a Monday Australian bourse filing.</p><p>The firm said that this was the first time a major private health insurer was funding a psychotherapy-led treatment-resistant depression program in Australia.</p><p>The firm's shares jumped 6% in recent trading on Monday and earlier reached their highest point in over a year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MPL.AU","symbol_name":"MEDIBANK PRIVATE LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2569272444","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569272444","pubTimestamp":1758509020,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Emyria  entered a multi-year agreement with Medibank  to fund treatment for screened and eligible customers admitted into the firm's treatment-resistant depression program at Perth Clinic, according to a Monday Australian bourse filing.The firm said that this was the first time a major private health insurer was funding a psychotherapy-led treatment-resistant depression program in Australia.The firm's shares jumped 6% in recent trading on Monday and earlier reached their highest point in over a year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MPL.AU":"MEDIBANK PRIVATE LTD","BK7502":"大麻概念","BK7089":"人寿与健康保险","BK7096":"制药","BK7113":"保健护理机构","EMD.AU":"Emyria Ltd"},"translate_title":"Emyria与Medibank就难治性抑郁症项目达成协议，股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMD.AU":1,"MPL.AU":1},"content_text":"Emyria (ASX:EMD) entered a multi-year agreement with Medibank (ASX: MPL) to fund treatment for screened and eligible customers admitted into the firm's treatment-resistant depression program at Perth Clinic, according to a Monday Australian bourse filing.The firm said that this was the first time a major private health insurer was funding a psychotherapy-led treatment-resistant depression program in Australia.The firm's shares jumped 6% in recent trading on Monday and earlier reached their highest point in over a year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}